Caribou Biosciences vs Innate Pharma
CRBU and IPHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and IPHA compare
Caribou Biosciences grew revenue faster over the last twelve months (1.6% versus −55.2% for Innate Pharma).
Caribou Biosciences scores higher on the StockData Score (8 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | IPHA |
|---|---|---|
| Size and price | ||
| Market cap | $38.8M | – |
| Share price | $0.362 | $1.38 |
| Change, 1 year | −84.0% | −28.1% |
| Change, 5 years | −98.3% | −72.5% |
| Beta (5Y) | 1.94 | 0.93 |
| Employees | 97 | 181 |
| StockData Score | ||
| Total score | 8 (better) | 0 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.1× | – |
| P/B | 0.5× | – |
| FCF yield | −240% | – |
| Fair value | $1.08 | – |
| Margin of safety | 66.4% | – |
| Growth | ||
| Revenue growth (TTM) | 1.6% (better) | −55.2% |
| Revenue growth, 5Y average | −2.0% (better) | −33.6% |
| Profitability | ||
| Operating margin | −1141% | −600% (better) |
| Net margin | −1085% | – |
| FCF margin | −985% | −587% (better) |
| Return on equity | −93.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −17.3× |
| Current ratio | 4.97 (better) | 0.60 |
| Altman Z-score | −9.18 | – |
| Piotroski F-score | 2 | – |
| Dividends and buybacks | ||
| Buyback yield | −69.3% | – |
| Shareholder yield | −69.3% | – |
| Ownership | ||
| Held by institutions | 45.5% | 0.21% |
| Held by insiders | 5.7% | 16.2% |
| Insider net buying, 12 months | −$47.5K | – |
| Short interest, % of float | 14.7% | – |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- IPHA stock overview
- IPHA income statement
- IPHA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.